Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 3
2021 4
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Patorno E, Pawar A, Wexler DJ, Glynn RJ, Bessette LG, Paik JM, Najafzadeh M, Brodovicz KG, Déruaz-Luyet A, Schneeweiss S. Patorno E, et al. Diabetes Obes Metab. 2022 Mar;24(3):442-454. doi: 10.1111/dom.14593. Epub 2021 Dec 1. Diabetes Obes Metab. 2022. PMID: 34729891 Free PMC article.
RESULTS: Study participants had a mean age of 60 years and only 28% had established cardiovascular disease. Compared to DPP-4 inhibitors, empagliflozin was associated with similar risk of MI/stroke (HR 0.99 [95% CI 0.81-1.21]), and lower risk of
RESULTS: Study participants had a mean age of 60 years and only 28% had established cardiovascular disease. Compared to DPP-4 inhibitors, …
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S. Patorno E, et al. Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8. Circulation. 2019. PMID: 30955357 Free PMC article.
BACKGROUND: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces the risk of hospitalization for hear
BACKGROUND: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) showed …
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Seino Y, Kim DJ, Yabe D, Tan EC, Chung WJ, Ha KH, Nangaku M, Node K, Klement R, Yasui A, Lei WY, Lee S, Kyaw MH, Deruaz-Luyet A, Brodovicz KG, H-H Sheu W; EMPRISE East Asia study group. Seino Y, et al. Endocrinol Diabetes Metab. 2020 Sep 16;4(1):e00183. doi: 10.1002/edm2.183. eCollection 2021 Jan. Endocrinol Diabetes Metab. 2020. PMID: 33532619 Free PMC article.
AIM: To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) East Asia study. ...This design reduces confounding due to switching treatments, time lag and immortal ti …
AIM: To evaluate the effectiveness of empagliflozin in clinical practice in East Asia in the Empagliflozin Comparative …
Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
Kim DJ, Sheu WH, Chung WJ, Yabe D, Ha KH, Nangaku M, Tan EC, Node K, Yasui A, Lei W, Lee S, Saarelainen L, Deruaz-Luyet A, Kyaw MH, Seino Y; EMPRISE East Asia Study Group. Kim DJ, et al. J Diabetes Investig. 2023 Mar;14(3):417-428. doi: 10.1111/jdi.13959. Epub 2023 Jan 30. J Diabetes Investig. 2023. PMID: 36716212 Free PMC article.
RESULTS: The study included 28,712 and 70,233 matched patient pairs for empagliflozin/DPP-4i and SGLT2i/DPP-4i analyses, respectively. The risk of composite outcomes including (i) hospitalization for heart failure (HHF) and all-cause mort …
RESULTS: The study included 28,712 and 70,233 matched patient pairs for empagliflozin/DPP-4i and SGLT2i/DPP-4i analyses, respectively …
The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.
Patorno E, Najafzadeh M, Pawar A, Franklin JM, Déruaz-Luyet A, Brodovicz KG, Santiago Ortiz AJ, Bessette LG, Kulldorff M, Schneeweiss S. Patorno E, et al. Endocrinol Diabetes Metab. 2019 Nov 26;3(1):e00103. doi: 10.1002/edm2.103. eCollection 2020 Jan. Endocrinol Diabetes Metab. 2019. PMID: 31922030 Free PMC article.
BACKGROUND: The EMPA-REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the ef …
BACKGROUND: The EMPA-REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospit
Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care.
Desai RJ, Glynn RJ, Everett BM, Schneeweiss S, Wexler DJ, Bessette LG, Déruaz-Luyet A, Vedin O, Brodovicz K, Patorno E. Desai RJ, et al. Am Heart J. 2022 Dec;254:203-215. doi: 10.1016/j.ahj.2022.09.008. Epub 2022 Sep 21. Am Heart J. 2022. PMID: 36150454
BACKGROUND: The effect of sodium glucose cotransporter 2 inhibitors (SGLT2i) on the total (first and recurrent) burden of cardiovascular (CV) hospitalizations, including hospitalization for heart failure, myocardial infarction, and stroke, is poorly un …
BACKGROUND: The effect of sodium glucose cotransporter 2 inhibitors (SGLT2i) on the total (first and recurrent) burden of cardiovascular (CV …
SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy.
Li N, Zhou H. Li N, et al. Drug Des Devel Ther. 2020 Nov 6;14:4775-4788. doi: 10.2147/DDDT.S269514. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33192053 Free PMC article. Review.
Sodium-glucose cotransporter type2 inhibitors (SGLT2Is) are a novel type of hypoglycemic agent in increasing urinary glucose and sodium excretion. Excitingly, the EMPA-REG clinical trial proved that empagliflozin significantly reduced the relative risk of
Sodium-glucose cotransporter type2 inhibitors (SGLT2Is) are a novel type of hypoglycemic agent in increasing urinary glucose and sodium excr …
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
This study compared risk of cardiovascular events in patients within routine care settings in Europe and Asia with type 2 diabetes (T2D) initiating empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP-4i) stratified by pre-existing C …
This study compared risk of cardiovascular events in patients within routine care settings in Europe and Asia wi …
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Najafzadeh M, Koeneman L, Farsani SF, Déruaz-Luyet A, Paik JM, Patorno E. Htoo PT, et al. JAMA Netw Open. 2022 Oct 3;5(10):e2237606. doi: 10.1001/jamanetworkopen.2022.37606. JAMA Netw Open. 2022. PMID: 36264574 Free PMC article.
Relative to patients initiating liraglutide, those initiating empagliflozin had a similar risk of the modified MACE outcome (HR, 0.90; 95% CI, 0.79-1.03) and a reduced risk of HHF (HR, 0.66; 95% CI, 0.52-0.82). ...These findings suggest that old …
Relative to patients initiating liraglutide, those initiating empagliflozin had a similar risk of the modified MACE out …
Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J. Real J, et al. Cardiovasc Diabetol. 2021 Jul 9;20(1):139. doi: 10.1186/s12933-021-01323-5. Cardiovasc Diabetol. 2021. PMID: 34243779 Free PMC article.

In the SGLT2i group, the exposure time was 60% for dapagliflozin, 26% for empagliflozin and 14% for canagliflozin. The use of SGLT2i was associated with a lower risk of heart failure (HR: 0.59; 95% confidence interval [CI] 0.47-0.74; p < 0.00

In the SGLT2i group, the exposure time was 60% for dapagliflozin, 26% for empagliflozin and 14% for canagliflozin. The use of SGLT2i …
11 results